FDA approves Veozah (Fezolinetant) for menopausal symptoms: a new nonhormonal option

Abstract

Menopausal vasomotor symptoms (VMS), such as hot flashes and night sweats, significantly impact the quality of life for many women. While hormone therapy remains a standard treatment, it is not suitable for all patients due to contraindications, safety concerns, or personal preferences. Fezolinetant (Veozah), a non-hormonal neurokinin-3 receptor (NK3R) antagonist, has emerged as a novel alternative for managing moderate to severe menopausal VMS. The U.S. Food and Drug Administration (FDA) approved Veozah on 12 May 2023, marking a milestone in the development of non-hormonal treatments for menopause-related symptoms. Fezolinetant modulates the activity of KNDy neurons in the hypothalamus, which plays a key role in thermoregulation. Clinical trials, including SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4, have demonstrated their efficacy in significantly reducing the frequency and severity of hot flashes. Additionally, long-term safety data indicate a well-tolerated profile with mild to moderate adverse effects, the most common being headache and fatigue. The approval of Veozah offers a safe and effective non-hormonal option for menopausal women who cannot or choose not to use hormone therapy. Its targeted mechanism addresses the underlying neurochemical dysregulation associated with VMS, providing rapid and sustained symptom relief. As research continues to explore its long-term impact, fezolinetant represents a promising advancement in women's health, improving the management of menopausal symptoms and enhancing overall well-being.